1. Disease Areas
  2. Cancer
  3. Melanoma

Melanoma

Melanoma is a serious form of skin cancer originating from melanocytes, the pigment-producing cells in the skin or mucosal surfaces, capable of spreading to distant organs such as lymph nodes, liver, lungs, and brain. It often appears as a changing mole with irregular features including asymmetry, uneven borders, varied colors, increased size, and evolving characteristics. Although less common than other skin cancers like basal cell and squamous cell carcinomas, melanoma is more aggressive and has a higher potential for metastasis, accounting for the majority of skin cancer-related deaths. Risk factors include a high number of moles, genetic predisposition, and prior history of melanoma. Early detection significantly improves outcomes, with approximately 90% of patients surviving at least five years after diagnosis. Treatment options include surgery, chemotherapy, radiation, immunotherapy, and targeted therapy. Melanoma can develop from existing moles or new skin growths and underscores the importance of skin cancer prevention, screening, and ongoing research.

References:

Melanoma (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14406
    L-733060 148700-85-0
    L-733060 is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 can be used for the study of chronic orofacial pain.
    L-733060
  • HY-179271
    CA/HDAC-IN-1
    CA/HDAC-IN-1 (Compound 11) is a CA and HDAC inhibitor with Ki values of 7.4 nM, 31.0 nM, and 7.3 nM for hCA II, hCA IX, and hCA XII, respectively, and IC50 values of 0.21 μM and 3.60 μM for HDAC3 and HDAC8, respectively. CA/HDAC-IN-1 has anti-cancer activity against colon cancer, breast cancer, and melanoma.
    CA/HDAC-IN-1